Literature DB >> 4845724

Serum levels of insulin-binding antibodies in diabetic patients treated with monocomponent insulin.

A Czyzyk, J Lawecki, H Rogala, E Miedzińska, A Popik-Hankiewicz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4845724     DOI： 10.1007/bf00423040

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  5 in total

1.  Liver disease and antibody formation.

Authors:  W P HAVENS
Journal:  Int Arch Allergy Appl Immunol       Date:  1959

2.  Clinical trial with monocomponent lente insulins. Preliminary report.

Authors:  B Bruni; M D'Alberto; M Osenda; C Ricci; G L Turco
Journal:  Diabetologia       Date:  1973-12       Impact factor: 10.122

3.  Radioimmunoelectrophoresis in the determination of insulin binding to IgG.

Authors:  A H Christiansen
Journal:  Horm Metab Res       Date:  1973-05       Impact factor: 2.936

4.  [Experiences with monocomponent insulin treatment].

Authors:  W Korp; R E Levett
Journal:  Wien Klin Wochenschr       Date:  1973-05-04       Impact factor: 1.704

5.  Clinical aspects of insulin--antigenicity.

Authors:  J Schlichtkrull; J Brange; A H Christiansen; O Hallund; L G Heding; K H Jorgensen
Journal:  Diabetes       Date:  1972       Impact factor: 9.461
  5 in total
  11 in total

1.  Hazards of monocomponent insulins.

Authors:  A W Logie; J M Stowers
Journal:  Br Med J       Date:  1976-04-10

2.  Highly purified insulins.

Authors:  K G Alberti; M Nattrass
Journal:  Diabetologia       Date:  1978-08       Impact factor: 10.122

3.  Serum insulin, insulin antibodies and insulin requirement in the first period of insulin treatment in non-insulin resistant diabetics.

Authors:  A Lev-Ran; L Ratt; N Gersht
Journal:  Acta Diabetol Lat       Date:  1975 Jan-Feb

4.  Local cutaneous allergy to monocomponent insulin.

Authors:  D Q Borsey; D N Malone
Journal:  Postgrad Med J       Date:  1979-03       Impact factor: 2.401

5.  The production and characteristics of anti-insulin, anti-A-component and anti-proinsulin antibodies in patients treated with monocomponent or conventional insulin.

Authors:  S Kawazu; Y Kanazawa; E Miki; M Hayashi; H Sando; H Kajinuma; Y Iwamoto; Y Akanuma; K Kosaka
Journal:  Acta Diabetol Lat       Date:  1979 Oct-Dec

6.  Antibody formation and insulin requirements in diabetic children during treatment with purified commercial pork insulins.

Authors:  B Weber; J Tech; H Schmidt; U Oberdisse
Journal:  Eur J Pediatr       Date:  1978-06-20       Impact factor: 3.183

7.  Proinsulin and A-component antibodies in diabetics after long-term monocomponent insulin treatment.

Authors:  B Bruni; S Gamba; G Regis; G L Turco
Journal:  Diabetologia       Date:  1978-03       Impact factor: 10.122

8.  Diabetic control in patients treated with once or twice-daily insulin injections, including a comparison of conventional beef and highly purified pork insulins.

Authors:  R S Gray; D Q Borsey; D M Fraser; A B Kurtz; S Rainbow; A F Smith; L J Duncan; B F Clarke
Journal:  Diabetologia       Date:  1981-09       Impact factor: 10.122

9.  Insulin-binding antibodies in serum of diabetic children treated with monocomponent insulin.

Authors:  A Symonides-Lawecka; H Ludwiczak; H Rogala; J Lawecki; A Czyzyk
Journal:  Acta Diabetol Lat       Date:  1974 Mar-Apr

10.  The immunogenic properties of a highly purified insulin preparation.

Authors:  N T Manning; M I Drury
Journal:  Ir J Med Sci       Date:  1979-12       Impact factor: 1.568
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.